The effects of subacute exposure to a water-soluble cannabinol compound in male mice.

Melissa M Bailey, Mariah C Emily Mills, Ashley E Haas, Kelly Bailey, Robert C Kaufmann
{"title":"The effects of subacute exposure to a water-soluble cannabinol compound in male mice.","authors":"Melissa M Bailey,&nbsp;Mariah C Emily Mills,&nbsp;Ashley E Haas,&nbsp;Kelly Bailey,&nbsp;Robert C Kaufmann","doi":"10.1186/s42238-022-00153-w","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Cannabinol (CBN) is one of the many cannabinoids present in Cannabis sativa and has been explored as a potential treatment for sleeplessness. The purpose of this study was to determine the physiological and behavioral effects of subacute exposure to therapeutic and low pharmacological levels of a mechanically formed, stabilized water-soluble cannabinol nano-emulsion (CBNight™).</p><p><strong>Methods: </strong>Sixty-two male mice were randomly assigned to one of six treatment groups given CBNight™ at dosages designed to deliver 0mg (control) to 4 mg/kg of CBN daily via oral gavage for 14 days. In-cage behavior was observed at 30 minutes and at 2, 4, 8, and 16 hours after each dose. After 14 days, the mice were sacrificed and necropsied. Organs were weighed and inspected for gross abnormalities, and blood was collected via cardiac puncture for clinical chemistry.</p><p><strong>Results: </strong>No dosage-dependent adverse effects on behavior, body mass, or blood chemistry were observed, except that the highest doses of CBNight™ were associated with significantly lower eosinophil counts.</p><p><strong>Conclusions: </strong>The commercially available, water-soluble CBN compound employed in this study does not appear to cause adverse effects in mice; rather, it appears to be well tolerated at pharmacological levels. The findings of eosinopenia at higher doses of CBN and lack of hepatotoxicity at any dosage employed in this study have not been reported to date.</p>","PeriodicalId":15172,"journal":{"name":"Journal of Cannabis Research","volume":" ","pages":"44"},"PeriodicalIF":0.0000,"publicationDate":"2022-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9327251/pdf/","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cannabis Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s42238-022-00153-w","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

Background: Cannabinol (CBN) is one of the many cannabinoids present in Cannabis sativa and has been explored as a potential treatment for sleeplessness. The purpose of this study was to determine the physiological and behavioral effects of subacute exposure to therapeutic and low pharmacological levels of a mechanically formed, stabilized water-soluble cannabinol nano-emulsion (CBNight™).

Methods: Sixty-two male mice were randomly assigned to one of six treatment groups given CBNight™ at dosages designed to deliver 0mg (control) to 4 mg/kg of CBN daily via oral gavage for 14 days. In-cage behavior was observed at 30 minutes and at 2, 4, 8, and 16 hours after each dose. After 14 days, the mice were sacrificed and necropsied. Organs were weighed and inspected for gross abnormalities, and blood was collected via cardiac puncture for clinical chemistry.

Results: No dosage-dependent adverse effects on behavior, body mass, or blood chemistry were observed, except that the highest doses of CBNight™ were associated with significantly lower eosinophil counts.

Conclusions: The commercially available, water-soluble CBN compound employed in this study does not appear to cause adverse effects in mice; rather, it appears to be well tolerated at pharmacological levels. The findings of eosinopenia at higher doses of CBN and lack of hepatotoxicity at any dosage employed in this study have not been reported to date.

亚急性暴露于一种水溶性大麻酚化合物对雄性小鼠的影响。
背景:大麻酚(CBN)是大麻中存在的许多大麻素之一,已被探索作为治疗失眠的潜在方法。本研究的目的是确定亚急性暴露于治疗性和低药理学水平的机械形成的,稳定的水溶性大麻酚纳米乳液(CBNight™)的生理和行为影响。方法:将62只雄性小鼠随机分为6个治疗组,给予CBNight™,剂量设计为每天口服CBN 0mg(对照)至4 mg/kg,持续14天。在每次给药后30分钟、2、4、8和16小时观察笼内行为。14天后,处死小鼠并进行尸检。对器官进行称重和检查是否有明显异常,并通过心脏穿刺采血进行临床化学检查。结果:除了最高剂量CBNight™与显著降低嗜酸性粒细胞计数相关外,未观察到对行为、体重或血液化学的剂量依赖性不良反应。结论:本研究中使用的市售水溶性CBN化合物似乎不会对小鼠产生不良影响;相反,它似乎在药理学水平上具有良好的耐受性。在本研究中,高剂量CBN引起的嗜酸性粒细胞减少以及在任何剂量下均无肝毒性的研究结果迄今尚未报道。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信